Quarterly report · Q2
9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥27.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.7bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥19.6bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥304m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥120m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥812m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥600m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.34 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.19 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | ¥22m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥8.1bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥761m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥11.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 17829000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.4500 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 4600000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1161 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 2136000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0539 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1514000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0382 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1140000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0288 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 937000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0237 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 804000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0203 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 648000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0164 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 487000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0123 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 458000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0116 | |
| Number of shares held | CurrentQuarterInstant | 30556000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.7713 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1300 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 39599200 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 395992 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 19480 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 39619980 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 395992 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 1300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 1300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 1300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Cash and deposits | Prior1YearInstant | 10767016000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 11036296000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 3910453000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 4171983000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant | 4406195000 | JPY |
| Electronically recorded monetary claims operating ca | CurrentQuarterInstant | 4961492000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 1415639000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 1409802000 | JPY |
| Work in process | Prior1YearInstant | 563125000 | JPY |
| Work in process | CurrentQuarterInstant | 454165000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |